Endoscopic outcome of medium term adalimumab therapy in patients with Crohn's disease. National data from Hungary
L Kiss, Z Czegledi, P Miheller, T Molnar, L Lakatos, K Palatka, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, I Altojay, F Nagy, J Papp, P Lakatos · Zeitschrift für Gastroenterologie · 2010 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background/Aims: Adalimumab (ADA) is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease in clinical trials. In Hungary, regular long-term ADA therapy became available on an outpatient basis in December 2008 (since September 2008 as donation). In the present study our aim was to analyse the endoscopic outcome during 1-year ADA therapy in patients with Crohn's disease in specialized centers approved for biological therapy in Hungary until the 1st of November 2009. Methods: Data of 139 CD patients were analyzed. (male/female: 61/78, mean age: 3…
